About Beta-1,3-galactosyltransferase 6
Beta-1,3-galactosyltransferase 6 (B3GALT6) is a protein
from Homo sapiens identified by UniProt accession
Q96L58, 329 residues long.
MolForge cross-references it against 0 known binders and
54 disease associations.
Target properties
| Protein name | Beta-1,3-galactosyltransferase 6 |
| UniProt accession | Q96L58 |
| Gene | B3GALT6 |
| Organism | Homo sapiens |
| Length | 329 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (54)
Diseases linked to this target (Open Targets).
- spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fractures · score 0.83
- Ehlers-Danlos syndrome, spondylodysplastic type, 2 · score 0.79
- Ehlers-Danlos syndrome, progeroid type · score 0.72
- Al-Gazali syndrome · score 0.60
- Ehlers-Danlos syndrome · score 0.56
- spondyloepimetaphyseal dysplasia with joint laxity · score 0.53
- Spondyloepiphyseal dysplasia and spondyloepimetaphyseal dysplasia · score 0.37
- spondyloepiphyseal dysplasia · score 0.27
- genetic disorder · score 0.19
- Crohn's disease · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96L58-F1 | alphafold | PREDICTED | 90.62 | — |
Amino-acid sequence (329 residues)
MKLLRRAWRR RAALGLGTLA LCGAALLYLA RCAAEPGDPR AMSGRSPPPP APARAAAFLA VLVASAPRAA ERRSVIRSTW LARRGAPGDV WARFAVGTAG LGAEERRALE REQARHGDLL LLPALRDAYE NLTAKVLAML AWLDEHVAFE FVLKADDDSF ARLDALLAEL RAREPARRRR LYWGFFSGRG RVKPGGRWRE AAWQLCDYYL PYALGGGYVL SADLVHYLRL SRDYLRAWHS EDVSLGAWLA PVDVQREHDP RFDTEYRSRG CSNQYLVTHK QSLEDMLEKH ATLAREGRLC KREVQLRLSY VYDWSAPPSQ CCQRREGIP
Explore Beta-1,3-galactosyltransferase 6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets